Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.9%

1 terminated/withdrawn out of 17 trials

Success Rate

93.3%

+6.8% vs industry average

Late-Stage Pipeline

53%

9 trials in Phase 3/4

Results Transparency

43%

6 of 14 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 4

9(56.3%)

N/A

3(18.8%)

Phase 1

2(12.5%)

Early Phase 1

1(6.3%)

Phase 2

1(6.3%)

16Total

Phase 4(9)

N/A(3)

Phase 1(2)

Early Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT04726371Not ApplicableCompleted

Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings

Role: collaborator

NCT01538199Not ApplicableCompleted

Transcranial Laser Therapy for Major Depressive Disorder

Role: collaborator

NCT00383747Phase 4Completed

The Effects of Nicotine on Cognition in Schizophrenia

Role: collaborator

NCT00351000Phase 4Completed

Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus

Role: lead

NCT00320697Phase 4Completed

Smoking Relapse Prevention in Schizophrenia

Role: lead

NCT01082588Phase 4Completed

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Role: collaborator

NCT00351936Phase 4Completed

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

Role: lead

NCT00499044Not ApplicableCompleted

A Comparison of Two Cognitive Batteries in People With Schizophrenia

Role: lead

NCT00575848Phase 1Terminated

Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia

Role: lead

NCT00573417Phase 4Completed

A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia

Role: lead

NCT00573300Completed

Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Study

Role: lead

NCT00320723Phase 4Completed

Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia

Role: lead

NCT00320736Phase 4Completed

Galantamine for Cognition in People With Schizophrenia

Role: lead

NCT00435903Early Phase 1Unknown

Pilot Study of the Feasibility of Palm Pilots in Monitoring Smoking Behavior in Individuals With Chronic Mental Illness

Role: lead

NCT00373126Phase 4Completed

The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia